These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9374903)

  • 1. Funding of drug treatment of multiple sclerosis should not be delayed.
    Paty DW
    BMJ; 1997 Nov; 315(7116):1160-1. PubMed ID: 9374903
    [No Abstract]   [Full Text] [Related]  

  • 2. Rebif offers another option for treating multiple sclerosis.
    Ryan M
    J Am Pharm Assoc (Wash); 2002; 42(6):889-91. PubMed ID: 12482017
    [No Abstract]   [Full Text] [Related]  

  • 3. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.
    Rice G
    Arch Neurol; 2001 Aug; 58(8):1297-8. PubMed ID: 11493173
    [No Abstract]   [Full Text] [Related]  

  • 4. Beta interferon and multiple sclerosis: why the fuss?
    Mumford CJ
    QJM; 1996 Jan; 89(1):1-3. PubMed ID: 8730337
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost utility of drugs for multiple sclerosis. Systematic review places study in contrast.
    Bryant J; Clegg A; Milne R
    BMJ; 2000 May; 320(7247):1474-5; author reply 1475-6. PubMed ID: 10877569
    [No Abstract]   [Full Text] [Related]  

  • 6. Bad decision NICE.
    Ellis SJ
    Lancet; 2002 Feb; 359(9304):447. PubMed ID: 11844551
    [No Abstract]   [Full Text] [Related]  

  • 7. A cost-utility analysis of interferon beta for multiple sclerosis.
    Parkin D; McNamee P; Jacoby A; Miller P; Thomas S; Bates D
    Health Technol Assess; 1998; 2(4):iii-54. PubMed ID: 9580870
    [No Abstract]   [Full Text] [Related]  

  • 8. [A short history of beta-interferon therapy of multiple sclerosis].
    Stock G; Horowski R
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shortcomings in pharmacy benefit forecasting--interferon beta products.
    Rich SJ; Meyer C
    J Manag Care Pharm; 2003; 9(4):373; author reply 374. PubMed ID: 14613461
    [No Abstract]   [Full Text] [Related]  

  • 10. The value of economic modeling studies in the evaluation of treatment strategies for multiple sclerosis.
    Detournay B
    Value Health; 2002; 5(1):1-2. PubMed ID: 11873378
    [No Abstract]   [Full Text] [Related]  

  • 11. [Interferon-beta in multiple sclerosis--who is going to be treated?].
    Aarli JA
    Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3114. PubMed ID: 10522472
    [No Abstract]   [Full Text] [Related]  

  • 12. Interferon beta in multiple sclerosis.
    Richards RG
    BMJ; 1996 Nov; 313(7066):1159. PubMed ID: 8916730
    [No Abstract]   [Full Text] [Related]  

  • 13. Interferon beta, PHARMAC, and political directives: in the best interests of people with multiple sclerosis?
    McNaughton H; Kayes N; McPherson K
    N Z Med J; 2006 Apr; 119(1232):U1939. PubMed ID: 16633398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Access denied. While the decision over beta-interferon prescribing hangs in the balance, one thing's for certain--nurses will be left to pick up the pieces.
    Thomas S
    Nurs Stand; 2000 Jul 19-25; 14(44):20. PubMed ID: 11975272
    [No Abstract]   [Full Text] [Related]  

  • 15. Shared scheme for assessing drugs for multiple sclerosis: why are eyes tightly shut to considering causes other than autoimmunity?
    Chaudhuri A; Behan PO
    BMJ; 2003 May; 326(7400):1213. PubMed ID: 12775634
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis.
    Nuijten MJ; Hutton J
    Value Health; 2002; 5(1):44-54. PubMed ID: 11873383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shared scheme for assessing drugs for multiple sclerosis: cost effective provision of effective treatments for multiple sclerosis.
    Napier JC; Francis R; Wright G
    BMJ; 2003 May; 326(7400):1212. PubMed ID: 12775633
    [No Abstract]   [Full Text] [Related]  

  • 18. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
    Clegg A; Bryant J; Milne R
    Health Technol Assess; 2000; 4(9):i-iv, 1-101. PubMed ID: 10944743
    [No Abstract]   [Full Text] [Related]  

  • 19. Interferon beta-1a and beta-1b for treatment of multiple sclerosis.
    Kappos L
    Lancet; 2002 Nov; 360(9343):1428; author reply 1428-9. PubMed ID: 12424020
    [No Abstract]   [Full Text] [Related]  

  • 20. [Betaferon and therapy of multiple sclerosis--present and future].
    Hohlfeld R
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():1. PubMed ID: 11603109
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.